Related Experiment Video
Updated: May 21, 2026
08:56
Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
Published on: October 7, 2021
Acquired peripheral neuropathy: a report on 20 children.
Summary
Guillain-Barré syndrome (GBS) is an inflammatory nerve disorder in children. This study reviews 20 pediatric cases, focusing on epidemiology, clinical presentation, and treatment.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Guillain-Barré syndrome (GBS) is an acute inflammatory polyneuropathy affecting children.
- It presents with rapid onset of symmetric muscle weakness, pain, and sensory disturbances.
- GBS incidence in children is 0.8 per 100,000, often following infections or vaccinations.
Discussion:
- The etiopathogenesis of GBS is thought to involve immune-mediated attacks on peripheral nerves.
- This case series analyzes epidemiologic, clinical, and therapeutic data from 20 pediatric patients.
- Understanding these features is crucial for timely diagnosis and management.
Key Insights:
- Pediatric GBS exhibits distinct epidemiological and clinical patterns.
- Infectious triggers and vaccination are common preceding events.
- Early recognition and appropriate management are vital for patient outcomes.
Outlook:
- Further research into GBS pathogenesis can refine treatment strategies.
- Long-term follow-up of pediatric GBS patients is essential.
- Investigating the specific immune mechanisms may lead to targeted therapies.
Related Concept Videos
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...